Baseline characteristics of ITP and control patient cohorts
| Baseline Characteristic . | ITP (n = 260) . | Control (n = 108) . |
|---|---|---|
| Age, median (range), y | 58 (18-92) | 67 (34-87) |
| Female, % | 52 | 25 |
| Total no. of PA assays included | 360 | 125 |
| Platelet count at time of PA assays, median (range), ×109/L | 71 (1-657)* | 106 (3-316) |
| ITP duration at time of initial evaluation, median (range), y | 1.0 (0.0-57.5) | |
| No. of previous therapies, median (range) | 2 (0-12) | |
| Postsplenectomy, % | 17 | |
| Corticosteroid responsive,† % | 87 | |
| IVIG responsive,‡ % | 84 | |
| Thrombopoietin receptor agonist responsive,§ % | 85 |
| Baseline Characteristic . | ITP (n = 260) . | Control (n = 108) . |
|---|---|---|
| Age, median (range), y | 58 (18-92) | 67 (34-87) |
| Female, % | 52 | 25 |
| Total no. of PA assays included | 360 | 125 |
| Platelet count at time of PA assays, median (range), ×109/L | 71 (1-657)* | 106 (3-316) |
| ITP duration at time of initial evaluation, median (range), y | 1.0 (0.0-57.5) | |
| No. of previous therapies, median (range) | 2 (0-12) | |
| Postsplenectomy, % | 17 | |
| Corticosteroid responsive,† % | 87 | |
| IVIG responsive,‡ % | 84 | |
| Thrombopoietin receptor agonist responsive,§ % | 85 |
Includes patients with active ITP only to prevent data skew (nearly all remission assays drawn with normal platelet count).
Requisite data available to assess response to glucocorticoids in 131 patients with ITP.
Requisite data available to assess response to IVIG in 76 patients with ITP.
Requisite data available to assess response to eltrombopag and/or romiplostim in 78 patients with ITP.